References
- Garofolo F , RocciML, DumontIet al. White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis3 (18), 2081–2096 (2011).
- Hill HM , SmeragliaJ, BrodieRR, SmithGT. Where do you draw the line? Points to consider when implementing the FDA method Guidance on quantifying chromatographic peaks. Chromatographia55 (1 Suppl. 1), S79–S81 (2002).
- Smith G , JamesCA, ScittR, WoolfE. Chromatographic baselines. Bioanalysis6 (9), 1167–1170 (2014).
- Hill HM , BakesD, LoveI. Manual chromatographic baseline integration: is it needed, if so when should it be used?Bioanalysis6 (9), 1171–1174 (2014).
- European Medicines Agency . Guideline on bioanalytical method validation 2011. www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2 011/08/WC500109686.pdf.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) , May 2001. Guidance for Industry Bioanalytical Method Validationwww.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
- Woolf EJ , McDougallS, FastDMet al. Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teams. AAPS J. 16 (5), 885–893 (2014).